Selected research
Industry Research
Biocompatibility Testing Industry Research Report 2026
Market perspective
The global Biocompatibility Testing market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biocompatibility Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biocompatibility Testing market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biocompatibility Testing market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biocompatibility Testing include Eurofins, Charles River, TUV SUD, Intertek Group, WuXi AppTec, LabCorp, Syensqo, SGS and Nelson Labs, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Biocompatibility Testing market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biocompatibility Testing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biocompatibility Testing Market by Company
Eurofins
Charles River
TUV SUD
Intertek Group
WuXi AppTec
LabCorp
Syensqo
SGS
Nelson Labs
Pacific BioLabs
Vantage MedTech
Cormica Lab (Wickham Micro)
CTI
CIRS
Shenzhen Advanced
Kerbio
CAS Testing
PONY Medicine
Tigermed
King Rock
Biocompatibility Testing Segment by Type
Cytotoxicity
Sensitization
Irritant
Pyrogen
Other
Biocompatibility Testing Segment by Application
Clinical
Non-clinical
Biocompatibility Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biocompatibility Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biocompatibility Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biocompatibility Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biocompatibility Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cytotoxicity
- Sensitization
- Irritant
- Pyrogen
- Other
Applications
- Clinical
- Non-clinical
Companies covered
- Eurofins
- Charles River
- TUV SUD
- Intertek Group
- WuXi AppTec
- LabCorp
- Syensqo
- SGS
- Nelson Labs
- Pacific BioLabs
- Vantage MedTech
- Cormica Lab (Wickham Micro)
- CTI
- CIRS
- Shenzhen Advanced
- Kerbio
- CAS Testing
- PONY Medicine
- Tigermed
- King Rock
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biocompatibility Testing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cytotoxicity
- 2.2.3 Sensitization
- 2.2.4 Irritant
- 2.2.5 Pyrogen
- 2.2.6 Other
- 2.3 Biocompatibility Testing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinical
- 2.3.3 Non-clinical
- 2.4 Assumptions and Limitations
3 Biocompatibility Testing Breakdown Data by Type
- 3.1 Global Biocompatibility Testing Historic Market Size by Type (2021-2026)
- 3.2 Global Biocompatibility Testing Forecasted Market Size by Type (2027-2032)
4 Biocompatibility Testing Breakdown Data by Application
- 4.1 Global Biocompatibility Testing Historic Market Size by Application (2021-2026)
- 4.2 Global Biocompatibility Testing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biocompatibility Testing Market Perspective (2021-2032)
- 5.2 Global Biocompatibility Testing Growth Trends by Region
- 5.2.1 Global Biocompatibility Testing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biocompatibility Testing Historic Market Size by Region (2021-2026)
- 5.2.3 Biocompatibility Testing Forecasted Market Size by Region (2027-2032)
- 5.3 Biocompatibility Testing Market Dynamics
- 5.3.1 Biocompatibility Testing Industry Trends
- 5.3.2 Biocompatibility Testing Market Drivers
- 5.3.3 Biocompatibility Testing Market Challenges
- 5.3.4 Biocompatibility Testing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biocompatibility Testing Players by Revenue
- 6.1.1 Global Top Biocompatibility Testing Players by Revenue (2021-2026)
- 6.1.2 Global Biocompatibility Testing Revenue Market Share by Players (2021-2026)
- 6.2 Global Biocompatibility Testing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biocompatibility Testing Head Office and Area Served
- 6.4 Global Biocompatibility Testing Players, Product Type & Application
- 6.5 Global Biocompatibility Testing Manufacturers Established Date
- 6.6 Global Biocompatibility Testing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biocompatibility Testing Market Size (2021-2032)
- 7.2 North America Biocompatibility Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biocompatibility Testing Market Size by Country (2021-2026)
- 7.4 North America Biocompatibility Testing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biocompatibility Testing Market Size (2021-2032)
- 8.2 Europe Biocompatibility Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biocompatibility Testing Market Size by Country (2021-2026)
- 8.4 Europe Biocompatibility Testing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biocompatibility Testing Market Size (2021-2032)
- 9.2 Asia-Pacific Biocompatibility Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biocompatibility Testing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biocompatibility Testing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biocompatibility Testing Market Size (2021-2032)
- 10.2 South America Biocompatibility Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biocompatibility Testing Market Size by Country (2021-2026)
- 10.4 South America Biocompatibility Testing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biocompatibility Testing Market Size (2021-2032)
- 11.2 Middle East & Africa Biocompatibility Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biocompatibility Testing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biocompatibility Testing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Eurofins
- 12.1.1 Eurofins Company Information
- 12.1.2 Eurofins Business Overview
- 12.1.3 Eurofins Revenue in Biocompatibility Testing Business (2021-2026)
- 12.1.4 Eurofins Biocompatibility Testing Product Portfolio
- 12.1.5 Eurofins Recent Developments
- 12.2 Charles River
- 12.2.1 Charles River Company Information
- 12.2.2 Charles River Business Overview
- 12.2.3 Charles River Revenue in Biocompatibility Testing Business (2021-2026)
- 12.2.4 Charles River Biocompatibility Testing Product Portfolio
- 12.2.5 Charles River Recent Developments
- 12.3 TUV SUD
- 12.3.1 TUV SUD Company Information
- 12.3.2 TUV SUD Business Overview
- 12.3.3 TUV SUD Revenue in Biocompatibility Testing Business (2021-2026)
- 12.3.4 TUV SUD Biocompatibility Testing Product Portfolio
- 12.3.5 TUV SUD Recent Developments
- 12.4 Intertek Group
- 12.4.1 Intertek Group Company Information
- 12.4.2 Intertek Group Business Overview
- 12.4.3 Intertek Group Revenue in Biocompatibility Testing Business (2021-2026)
- 12.4.4 Intertek Group Biocompatibility Testing Product Portfolio
- 12.4.5 Intertek Group Recent Developments
- 12.5 WuXi AppTec
- 12.5.1 WuXi AppTec Company Information
- 12.5.2 WuXi AppTec Business Overview
- 12.5.3 WuXi AppTec Revenue in Biocompatibility Testing Business (2021-2026)
- 12.5.4 WuXi AppTec Biocompatibility Testing Product Portfolio
- 12.5.5 WuXi AppTec Recent Developments
- 12.6 LabCorp
- 12.6.1 LabCorp Company Information
- 12.6.2 LabCorp Business Overview
- 12.6.3 LabCorp Revenue in Biocompatibility Testing Business (2021-2026)
- 12.6.4 LabCorp Biocompatibility Testing Product Portfolio
- 12.6.5 LabCorp Recent Developments
- 12.7 Syensqo
- 12.7.1 Syensqo Company Information
- 12.7.2 Syensqo Business Overview
- 12.7.3 Syensqo Revenue in Biocompatibility Testing Business (2021-2026)
- 12.7.4 Syensqo Biocompatibility Testing Product Portfolio
- 12.7.5 Syensqo Recent Developments
- 12.8 SGS
- 12.8.1 SGS Company Information
- 12.8.2 SGS Business Overview
- 12.8.3 SGS Revenue in Biocompatibility Testing Business (2021-2026)
- 12.8.4 SGS Biocompatibility Testing Product Portfolio
- 12.8.5 SGS Recent Developments
- 12.9 Nelson Labs
- 12.9.1 Nelson Labs Company Information
- 12.9.2 Nelson Labs Business Overview
- 12.9.3 Nelson Labs Revenue in Biocompatibility Testing Business (2021-2026)
- 12.9.4 Nelson Labs Biocompatibility Testing Product Portfolio
- 12.9.5 Nelson Labs Recent Developments
- 12.10 Pacific BioLabs
- 12.10.1 Pacific BioLabs Company Information
- 12.10.2 Pacific BioLabs Business Overview
- 12.10.3 Pacific BioLabs Revenue in Biocompatibility Testing Business (2021-2026)
- 12.10.4 Pacific BioLabs Biocompatibility Testing Product Portfolio
- 12.10.5 Pacific BioLabs Recent Developments
- 12.11 Vantage MedTech
- 12.11.1 Vantage MedTech Company Information
- 12.11.2 Vantage MedTech Business Overview
- 12.11.3 Vantage MedTech Revenue in Biocompatibility Testing Business (2021-2026)
- 12.11.4 Vantage MedTech Biocompatibility Testing Product Portfolio
- 12.11.5 Vantage MedTech Recent Developments
- 12.12 Cormica Lab (Wickham Micro)
- 12.12.1 Cormica Lab (Wickham Micro) Company Information
- 12.12.2 Cormica Lab (Wickham Micro) Business Overview
- 12.12.3 Cormica Lab (Wickham Micro) Revenue in Biocompatibility Testing Business (2021-2026)
- 12.12.4 Cormica Lab (Wickham Micro) Biocompatibility Testing Product Portfolio
- 12.12.5 Cormica Lab (Wickham Micro) Recent Developments
- 12.13 CTI
- 12.13.1 CTI Company Information
- 12.13.2 CTI Business Overview
- 12.13.3 CTI Revenue in Biocompatibility Testing Business (2021-2026)
- 12.13.4 CTI Biocompatibility Testing Product Portfolio
- 12.13.5 CTI Recent Developments
- 12.14 CIRS
- 12.14.1 CIRS Company Information
- 12.14.2 CIRS Business Overview
- 12.14.3 CIRS Revenue in Biocompatibility Testing Business (2021-2026)
- 12.14.4 CIRS Biocompatibility Testing Product Portfolio
- 12.14.5 CIRS Recent Developments
- 12.15 Shenzhen Advanced
- 12.15.1 Shenzhen Advanced Company Information
- 12.15.2 Shenzhen Advanced Business Overview
- 12.15.3 Shenzhen Advanced Revenue in Biocompatibility Testing Business (2021-2026)
- 12.15.4 Shenzhen Advanced Biocompatibility Testing Product Portfolio
- 12.15.5 Shenzhen Advanced Recent Developments
- 12.16 Kerbio
- 12.16.1 Kerbio Company Information
- 12.16.2 Kerbio Business Overview
- 12.16.3 Kerbio Revenue in Biocompatibility Testing Business (2021-2026)
- 12.16.4 Kerbio Biocompatibility Testing Product Portfolio
- 12.16.5 Kerbio Recent Developments
- 12.17 CAS Testing
- 12.17.1 CAS Testing Company Information
- 12.17.2 CAS Testing Business Overview
- 12.17.3 CAS Testing Revenue in Biocompatibility Testing Business (2021-2026)
- 12.17.4 CAS Testing Biocompatibility Testing Product Portfolio
- 12.17.5 CAS Testing Recent Developments
- 12.18 PONY Medicine
- 12.18.1 PONY Medicine Company Information
- 12.18.2 PONY Medicine Business Overview
- 12.18.3 PONY Medicine Revenue in Biocompatibility Testing Business (2021-2026)
- 12.18.4 PONY Medicine Biocompatibility Testing Product Portfolio
- 12.18.5 PONY Medicine Recent Developments
- 12.19 Tigermed
- 12.19.1 Tigermed Company Information
- 12.19.2 Tigermed Business Overview
- 12.19.3 Tigermed Revenue in Biocompatibility Testing Business (2021-2026)
- 12.19.4 Tigermed Biocompatibility Testing Product Portfolio
- 12.19.5 Tigermed Recent Developments
- 12.20 King Rock
- 12.20.1 King Rock Company Information
- 12.20.2 King Rock Business Overview
- 12.20.3 King Rock Revenue in Biocompatibility Testing Business (2021-2026)
- 12.20.4 King Rock Biocompatibility Testing Product Portfolio
- 12.20.5 King Rock Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst